Esperoct is used to treat hemophilia A in adults and children [1]. It is a recombinant factor VIII (FVIII) molecule that is engineered to have a longer half-life [2].
How does Esperoct work?
Esperoct works by replacing the missing or defective factor VIII in individuals with hemophilia A. Factor VIII is a protein that plays a crucial role in blood clotting. By providing a functional FVIII molecule, Esperoct helps to prevent or stop bleeding episodes [1]. The longer half-life of Esperoct means that it stays in the body for an extended period, potentially allowing for less frequent infusions compared to some other factor VIII therapies [2].
What is the difference between Esperoct and other hemophilia A treatments?
Esperoct is a prophylaxis treatment, meaning it is given regularly to prevent bleeding episodes. It is a long-acting recombinant factor VIII (rFVIII) product. Other treatments for hemophilia A include on-demand therapy (infusions given only when bleeding occurs) and other prophylactic rFVIII products with varying half-lives. Esperoct's engineered structure allows for extended circulation in the bloodstream, which can translate to less frequent dosing schedules for patients [2][3].
When does Esperoct's patent expire?
Information regarding the specific patent expiration dates for Esperoct is not readily available in the provided context. Drug patent information can be complex and involve multiple patents covering different aspects of a drug. Resources like DrugPatentWatch.com may offer detailed insights into patent statuses and expiry timelines for pharmaceutical products [4].
Who makes Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
What are the clinical results for Esperoct?
Clinical trials have demonstrated Esperoct's efficacy in reducing annualized bleeding rates (ABR) in patients with hemophilia A. In studies, Esperoct has shown a significant reduction in bleeding events compared to previous prophylaxis regimens [2]. The drug is approved for use in individuals of all ages with hemophilia A [1].